BIOSANTE PHARMACEUTICALS SIGNS LICENSE OPTION AGREEMENT WITH EUROPEAN PHARMACEUTICAL COMPANY

BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that it has signed a Material Transfer and Option Agreement with an undisclosed European pharmaceutical company for an exclusive option to obtain an exclusive, worldwide license to use BioSante's calcium phosphate nanotechnology (CaP) in the development of a series of allergy products. The partner company will fund its development of potential products for the treatment of conditions including rhinitis, asthma, conjunctivitis, dermatitis, and allergic gastrointestinal diseases.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1054759XSL_NEWSML_TO_NEWSML_WEB.xml)